Finance

Lists
ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
၇.၄၅ US$
-၁.၉၇%
(-၀.၁၅) 1D
၇.၅၅ US$
+၁.၃၄% (+၀.၁၀)
After hours
Closed: နို ၂၀, GMT-၅ ၁၆:၀၀:၀၂  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARCT...
Open
၇.၄၀ US$
High
၇.၇၃ US$
Low
၇.၃၁ US$
Mkt. cap
၂၁.၄၇ ကုဋေ
Avg. vol.
၆.၅၂ သိန်း
Volume
၆.၀၂ သိန်း
52-wk high
၁၇.၉၆ US$
52-wk low
၅.၅၀ US$
EPS
-၃.၀၈ US$
Beta
၂.၆၂
Shares outstanding
၂.၈၈ ကုဋေ
No. of employees
၁၀၉
Open
၇.၄၀ US$
High
၇.၇၃ US$
Low
၇.၃၁ US$
Mkt. cap
၂၁.၄၇ ကုဋေ
Avg. vol.
၆.၅၂ သိန်း
Volume
၆.၀၂ သိန်း
52-wk high
၁၇.၉၆ US$
52-wk low
၅.၅၀ US$
EPS
-၃.၀၈ US$
Beta
၂.၆၂
Shares outstanding
၂.၈၈ ကုဋေ
No. of employees
၁၀၉
News stories
From web sources and news partners
The Motley Fool
The Motley Fool
·
ပြီးခဲ့သည့် ၃၄ မိနစ်
If the S&P 500 Drops by 20%, I'm Buying These 3 ETFs Without Hesitation
Traders Union
Traders Union
·
ပြီးခဲ့သည့် ၅၃ မိနစ်
Seventeen of the twenty largest S&P 500 drops began below the 200-day moving average, Ryan Detrick notes
24/7 Wall St.
24/7 Wall St.
·
ပြီးခဲ့သည့် ၃၂ မိနစ်
Jim Cramer Says the Market “Sliced Right Through” His S&P 500 Target
TradingView
TradingView
·
ပြီးခဲ့သည့် ၃ နာရီ
Stock Market Crash: Nasdaq, S&P 500 Suffer Worst Weekly Losses in Years
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc
CEOJoseph E. Payne
Employees၁၀၉
Founded၂၀၁၃
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 9 analysts giving stock ratings to ARCT in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ARCT in the last 3 months.
Highest
Current ၇.၄၅ US$
၄၀.၀၀ US$ (+၄၃၆.၉၁%)
Average
၂၁.၂၅ US$ (+၁၈၅.၂၃%)
Lowest
၉.၀၀ US$ (+၂၀.၈၁%)
Analyst
Recommendation
Action
Price target
Projected
Date
Adam Walsh
Roth MKM
Buy
Maintained
၄၀.၀၀ US$
+၄၃၆.၉%
11/16/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
၂၀.၀၀ US$
+၁၆၈.၅%
11/09/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
၂၀.၀၀ US$
+၁၆၈.၅%
11/06/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
၂၂.၀၀ US$
+၁၉၅.၃%
11/06/2026
Thomas Shrader
BTIG
Buy
Maintained
၂၀.၀၀ US$
+၁၆၈.၅%
11/06/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
၁၉.၀၀ US$
+၁၅၅%
10/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
၂၀.၀၀ US$
+၁၆၈.၅%
10/02/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
09/24/2026
Andrew Fein
H.C. Wainwright
Hold
Reiterated
၉.၀၀ US$
+၂၀.၈%
09/24/2026
Yigal Nochomovitz
Citi
Buy
Upgraded
၂၀.၀၀ US$
+၁၆၈.၅%
09/24/2026
Unknown Analyst
Citi
Hold
Maintained
၈.၀၀ US$
+၇.၄%
09/09/2026
Seamus Fernandez
Guggenheim
Hold
Maintained
-
-
08/06/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Initiated
၂၇.၀၀ US$
+၂၆၂.၄%
07/02/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
၂၂.၀၀ US$
+၁၉၅.၃%
03/18/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
၂၅.၀၀ US$
+၂၃၅.၆%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၇.၂၀ သန်း
၂.၀၆ သန်း
၂.၉၆ သန်း
၁.၈၃ ကုဋေ
Cost of goods sold
၂.၄၅ ကုဋေ
၂.၁၅ ကုဋေ
၁.၇၅ ကုဋေ
၁.၇၀ ကုဋေ
Cost of revenue
၂.၄၅ ကုဋေ
၂.၁၅ ကုဋေ
၁.၇၅ ကုဋေ
၁.၇၀ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၄၀ ကုဋေ
၉.၄၆ သန်း
၁.၁၀ ကုဋေ
၁.၀၅ ကုဋေ
Operating expense
၁.၄၀ ကုဋေ
၉.၄၆ သန်း
၁.၁၀ ကုဋေ
၁.၀၅ ကုဋေ
Total operating expenses
၃.၈၅ ကုဋေ
၃.၁၀ ကုဋေ
၂.၈၅ ကုဋေ
၂.၇၅ ကုဋေ
Operating income
-၃.၁၃ ကုဋေ
-၂.၈၉ ကုဋေ
-၂.၅၅ ကုဋေ
-၉.၁၈ သန်း
Other non operating income
-
၃.၅၀ သောင်း
-၅.၉၀ သောင်း
-၂.၀၀ ထောင်
EBT including unusual items
-၂.၉၁ ကုဋေ
-၂.၇၀ ကုဋေ
-၂.၃၈ ကုဋေ
-၇.၄၁ သန်း
EBT excluding unusual items
-၂.၉၁ ကုဋေ
-၂.၇၀ ကုဋေ
-၂.၃၈ ကုဋေ
-၇.၄၁ သန်း
Income tax expense
-၄.၀၀ ထောင်
-
-
-
Effective tax rate
၀.၀၁%
-
-
-
Other operating expenses
-
-
-
-
Net income
-၂.၉၁ ကုဋေ
-၂.၇၀ ကုဋေ
-၂.၃၈ ကုဋေ
-၇.၄၁ သန်း
Net profit margin
-၄၀၄.၁၀%
-၁,၃၀၈.၃၀%
-၈၀၃.၈၂%
-၄၀.၅၂%
Earnings per share
-၁.၀၃
-၀.၉၅
-၀.၈၄
-၀.၂၆
Interest and investment income
၁.၅၃ သန်း
၁.၉၃ သန်း
၁.၈၂ သန်း
၁.၇၇ သန်း
Interest expense
-၉.၀၀ ထောင်
-
-
-
Net interest expenses
၁.၅၂ သန်း
၁.၉၃ သန်း
၁.၈၂ သန်း
၁.၇၇ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၃.၀၆ ကုဋေ
-၂.၈၃ ကုဋေ
-၂.၄၉ ကုဋေ
-၈.၅၈ သန်း
Gain or loss from assets sale
-
-၃.၄၀ သောင်း
၅.၄၀ သောင်း
၈.၀၀ ထောင်
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ